Akums Drugs and Pharmaceuticals Limited, a prominent player in the pharmaceutical contract development and manufacturing organisation (CDMO) space, is set to launch its IPO on July 30, 2024. Let's delve into the details of this significant offering.
About Akums Drugs and Pharmaceuticals Limited
Established in 2004, Akums Drugs has emerged as a leading CDMO, offering a comprehensive range of pharmaceutical products and services. Their core competencies lie in product development, manufacturing, research and development (R&D), regulatory submissions, and branded drug and API production. The company boasts a strong track record of serving 26 out of the top 30 pharmaceutical companies in India.
Akums Drugs IPO fundamentals
- Issue Type: Book Built Issue
- Issue Size: ₹ 1,856.74 Crore
- Issue Composition: Fresh Issue (₹ 680 Crore) + Offer for Sale (₹ 1,176.74 Crore)
- Offer Period: July 30, 2024 - August 1, 2024
- Expected Allotment: August 2, 2024
- Listing Venue: BSE, NSE (tentative listing date: August 6, 2024)
- Price Band: ₹ 646 - ₹ 679 per share
- Minimum Lot Size: 22 Shares (Retail Investors: ₹ 14,938 minimum investment)
- HNI/sNII/bNII Minimum Lot: 14/67 Lots (₹ 209,132/₹ 1,000,846 minimum investment)
Akums Drugs IPO review: strengths
- Comprehensive Offerings: Akums Drugs provides a wide range of dosage forms, catering to diverse pharmaceutical needs.
- Manufacturing Capacity: With 10 manufacturing units and a capacity of 49.21 billion units annually, the company has a strong production base.
- Regulatory Compliance: Accreditations from EU-GMP, WHO-GMP, and US NSF underscore the company's commitment to quality and compliance.
- Strong Client Base: Collaborations with top pharmaceutical companies highlight the company's market position.
Akums Drugs IPO review: considerations
- Profitability Concerns: The significant drop in PAT in FY 2024 raises concerns about profitability. Investors should carefully analyse the reasons behind this decline before investing in the Akums Drugs IPO.
- Competitive Landscape: The pharmaceutical CDMO market is highly competitive. Assessing Akums Drugs' competitive advantage is crucial.
- Regulatory Risks: The pharmaceutical industry is subject to stringent regulations. Any changes in regulations could impact the company's operations. Make sure you take that into consideration before your IPO investment.
Conclusion
Akums Drugs IPO presents an opportunity to invest in a growing CDMO with a strong market presence. However, the recent decline in profitability and the competitive landscape warrants careful consideration. Investors should thoroughly evaluate the company's financials, growth prospects, and risk factors before making a decision. Consulting with a financial advisor can provide valuable insights.
Disclaimer: This blog is for informational purposes only and should not be considered as investment advice. It's advisable to consult with a financial advisor before investing in any IPO.
